Low StockRetatrutide 10mg
10mg | $139.00Retatrutide is a triple-agonist — a single molecule engaging GLP-1, GIP, and glucagon receptors simultaneously.
The three pathways are tuned to work in coordination:
• GIP (2× native) — insulin efficiency, adipose signaling
• GLP-1 (0.5× native) — appetite moderation
• Glucagon (0.2× native) — hepatic fat mobilization, metabolic rate maintenance
In 48-week Phase 2 trials, it showed 24% weight loss and 86% liver fat reduction — numbers that exceed both single-agonist (semaglutide) and dual-agonist (tirzepatide) compounds.
The glucagon pathway is the key differentiator: it signals the liver to mobilize and oxidize stored triglycerides directly, and counteracts the metabolic slowdown typical of weight loss with a modest heart rate increase (2-7 bpm in trials).
Phase III trials are ongoing.
- Active Hepatic Fat MobilizationGlucagon receptor activation signals the liver to mobilize and oxidize stored triglycerides directly. This is active fat mobilization, not passive reduction through caloric deficit — explaining the 86% liver fat reduction in trials.
- Metabolic Rate MaintenanceThe glucagon component maintains resting energy expenditure during caloric deficit, counteracting the metabolic slowdown typical of weight loss. This comes with a modest heart rate increase (2-7 bpm).
- Coordinated Pathway TuningGIP at 2× native affinity for insulin efficiency, GLP-1 at 0.5× for appetite moderation, glucagon at 0.2× for hepatic effects. The ratios are tuned to work in coordination rather than compete.
- Enhanced GIP SignalingGIP pathway at 2× native affinity strengthens insulin responsiveness and has direct effects on adipose tissue, lowering the hormonal cost of glycemic control.
1
For in-vitro laboratory research use only. Not for human consumption.